"Contact Investigation Under Way; Risk to Other Travelers Considered Extremely Low
The CDC and the Minnesota Department of Health (MDH) have confirmed a diagnosis of Lassa fever in a person returning to the United States from West Afri"...
Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria
Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (eg, erythromycin).
Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tuboovarian abscess, pelvic cellulitis and postsurgical vaginal cuff infection.
Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections.
Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections.
Pneumococci: Serious respiratory tract infections.
Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of CLEOCIN (clindamycin) HCl and other antibacterial drugs, CLEOCIN (clindamycin) HCl should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
DOSAGE AND ADMINISTRATION
If significant diarrhea occurs during therapy, this antibiotic should be discontinued (see WARNING box).
Serious infections—150 to 300 mg every 6 hours. More severe infections—300 to 450 mg every 6 hours. Pediatric Patients: Serious infections—8 to 16 mg/kg/day (4 to 8 mg/lb/day) divided into three or four equal doses. More severe infections—16 to 20 mg/kg/day (8 to 10 mg/lb/day) divided into three or four equal doses.
To avoid the possibility of esophageal irritation, CLEOCIN (clindamycin) HCl Capsules should be taken with a full glass of water.
Serious infections due to anaerobic bacteria are usually treated with CLEOCIN (clindamycin) PHOSPHATE® Sterile Solution. However, in clinically appropriate circumstances, the physician may elect to initiate treatment or continue treatment with CLEOCIN (clindamycin) HCl Capsules.
In cases of β-hemolytic streptococcal infections, treatment should continue for at least 10 days.
CLEOCIN (clindamycin) HCl Capsules are available in the following strengths, colors and sizes:
|75 mg Green|
|Bottles of 100||NDC 0009-0331-02|
|150 mg Light Blue and Green|
|Bottles of 16||NDC 0009-0225-01|
|Bottles of 100||NDC 0009-0225-02|
|Unit dose package of 100||NDC 0009-0225-03|
|300 mg Light Blue|
|Bottles of 16||NDC 0009-0395-13|
|Bottles of 100||NDC 0009-0395-14|
|Unit dose package of 100||NDC 0009-0395-02|
Store at controlled room temperature 20° to 25° C (68° to 77° F) [see USP].
Manufactured by: Pharmacia and Upjohn Company
Last reviewed on RxList: 1/13/2010
This monograph has been modified to include the generic and brand name in many instances.
Additional Cleocin Information
Cleocin - User Reviews
Cleocin User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.